[HTML][HTML] Noncoding mutations target cis-regulatory elements of the FOXA1 plexus in prostate cancer

S Zhou, JR Hawley, F Soares, G Grillo, M Teng… - Nature …, 2020 - nature.com
Nature communications, 2020nature.com
Prostate cancer is the second most commonly diagnosed malignancy among men
worldwide. Recurrently mutated in primary and metastatic prostate tumors, FOXA1 encodes
a pioneer transcription factor involved in disease onset and progression through both
androgen receptor-dependent and androgen receptor-independent mechanisms. Despite its
oncogenic properties however, the regulation of FOXA1 expression remains unknown. Here,
we identify a set of six cis-regulatory elements in the FOXA1 regulatory plexus harboring …
Abstract
Prostate cancer is the second most commonly diagnosed malignancy among men worldwide. Recurrently mutated in primary and metastatic prostate tumors, FOXA1 encodes a pioneer transcription factor involved in disease onset and progression through both androgen receptor-dependent and androgen receptor-independent mechanisms. Despite its oncogenic properties however, the regulation of FOXA1 expression remains unknown. Here, we identify a set of six cis-regulatory elements in the FOXA1 regulatory plexus harboring somatic single-nucleotide variants in primary prostate tumors. We find that deletion and repression of these cis-regulatory elements significantly decreases FOXA1 expression and prostate cancer cell growth. Six of the ten single-nucleotide variants mapping to FOXA1 regulatory plexus significantly alter the transactivation potential of cis-regulatory elements by modulating the binding of transcription factors. Collectively, our results identify cis-regulatory elements within the FOXA1 plexus mutated in primary prostate tumors as potential targets for therapeutic intervention.
nature.com